Frontiers in Physiology

SEP 4, 2026 · JOURNAL ARTICLE

Restructuring the gut microbiota in obesity: molecular mechanisms linking dysbiosis to systemic inflammation and therapeutic opportunities

Frontiers in Physiology

This is a narrative review synthesizing mechanistic evidence and existing studies without new primary data, raising and exploring questions about dysbiosis-inflammation pathways rather than answering them with original results.

SEP 2, 2026 · REVIEW

Pulmonary sequelae of SARS-CoV-2 infection: a narrative review of long-term functional, radiological, and clinical outcomes in COVID-19 survivors, with a regional focus on Saudi Arabia

Frontiers in Physiology

A narrative review synthesizing current evidence on long-term pulmonary sequelae of COVID-19, identifying reduced DLCO as the most prevalent finding and calling for standardized research and rehabilitation approaches.

AUG 19, 2026 · JOURNAL ARTICLE

From single-pathway cascade to network pathophysiology: how genetically engineered mouse models reshaped our understanding of pancreatitis

Frontiers in Physiology

This is a mechanistic synthesis and conceptual reframing of pancreatitis pathophysiology based on preclinical genetically engineered mouse models, raising a network-based hypothesis rather than reporting a clinical trial or definitive human evidence.

AUG 10, 2026 · JOURNAL ARTICLE

Reactive oxygen species regulation of ferroptosis, autophagy, apoptosis, and immunogenic cell death in cancer

Frontiers in Physiology

A narrative review synthesizing mechanistic pathways of ROS-dependent cell death in cancer, raising questions about therapeutic targeting rather than reporting empirical trial results.

AUG 10, 2026 · JOURNAL ARTICLE

Propofol for depression: mechanisms and therapeutic potential

Frontiers in Physiology

A narrative review synthesizing preliminary open-label clinical evidence and putative mechanisms without new empirical data; the source itself acknowledges small sample sizes, lack of controlled trials, and unresolved safety and dosing questions, positioning propofol as a candidate for future study rather than an established therapeutic.